bioprinted therapeutic News
-
Aspect Biosystems to Present at 2021 Virtual Cell & Gene Meeting on the Med
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, has announced that President & CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mediterranean to be held virtually April 6-9, 2021. This is the second time that the company will be presenting at this conference. The Business Development Team from Aspect ...
-
Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...
-
Aspect Biosystems Appoints Ray Smith as Chief Financial Officer
Aspect Biosystems, a biotechnology company developing bioprinted therapeutics, is pleased to announce the appointment of Ray Smith as its new Chief Financial Officer. In his role as Chief Financial Officer, Ray will assume leadership responsibilities for financial management and business operations. “Since leaving the University of British Columbia’s campus and launching our ...
-
Aspect Biosystems To Present New Data At International Pancreas And Islet Transplant Association (Ipita) Congress 2021
Bioprinted pancreatic tissues successfully regulate blood glucose in animal models of type 1 diabetes Vancouver, BC, Canada, October 13, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present the Company’s latest data on its bioprinted pancreas therapeutic program at the International Pancreas and ...
-
Aspect Biosystems Strengthens Expertise In Cell Therapy Development With Additions To Leadership Team
Jack Harvey joins the company as Senior Vice President of Process Development & Manufacturing and Rafal P. Witek joins as Head of Therapeutic Cell Platforms VANCOUVER, British Columbia – September 28, 2021 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce the addition of ...
-
3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to its Board of Directors. Dr. Barer is the former CEO and Chairman of Celgene and currently serves as Chairman of Teva Pharmaceuticals. Dr. Slawin, Founder and Managing Partner of Rapha Capital Management, previously founded ...
-
3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia. Microtia is a rare congenital disorder causing the outer ear (auricle) to be smaller than typical, misshapen, and sometimes ...
-
3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia. Microtia is a rare congenital disorder causing the outer ear ...
-
Poietis announces formation of Scientific Advisory Board and appoints two first prominent Regenerative Medicine experts
Poietis, 4D Bioprinting company, announces formation of Scientific Advisory Board (SAB) and appointment of two first prominent Scientists in Regenerative Medicine. The SAB will serve as a key strategic resource to Poietis as the company expands capabilities of Next- Generation Bioprinting (NGB) platform to therapeutic applications and develops first implantable tissues such as a ...
By Poietis
-
Poietis and Prometheus, division of skeletal tissue engineering of KU Leuven, enter into a Collaborative Research Agreement focused on 3D Bioprinting for skeletal ATMPs.
Poietis, leading bioprinting company and Prometheus, Division of Skeletal Tissue Engineering at KU Leuven, entered into a 2-years Collaborative Research Agreement focused on high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration. Prometheus focuses on the bench-to-bedside clinical translation of increasingly ...
By Poietis
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you